ClinicalTrials.gg
CompletedNCT03084471STRONGUpdated Dec 22, 2022Results posted

An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.

A Phase 3 interventional study of MEDI4736 (Durvalumab) and MEDI4736 (Durvalumab) + Tremelimumab in Advanced Solid Malignancies, sponsored by AstraZeneca. Completed at 79 sites in 8 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2022-12-22.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
867
Allocation
Non-randomized
Ages
18 Years to 130 Years
Sex
All
01

Study summary

To evaluate the safety, tolerability, and anti-tumor activity of the combination of durvalumab + tremelimumab or durvalumab alone in different solid tumors.

Read the detailed description

This is an open-label, multi-center, study to determine the short and long term safety of fixed doses of durvalumab 1500 mg + tremelimumab 75 mg combination therapy or durvalumab 1500 mg monotherapy in patients with advanced solid malignancies. This study is modular in design, one or more of the modules will be opened in a given country / region based on local patient population prevalence, and results of feasibility studies. The total number of patients to be enrolled overall and in each module will depend on the types and number of tumor modules added to the main study and country-specific ancillary studies. The number of patients and sites to be involved in individual countries will be dependent on each module or ancillary study. This study consisted of a screening period, a treatment period, a 90 day safety follow-up period and a survival follow-up period. Patients will receive the investigation product (IP) via intravenous (IV) infusion once every 4 weeks (Q4W) in combination therapy or monotherapy as mentioned below - Combination therapy: Durvalumab 1,500 mg + tremelimumab 75 mg on Week 0, for up to a maximum of 4 doses (or cycles) followed by durvalumab 1,500 mg starting 4 weeks after the last infusion of the combination or discontinuation of tremelimumab.

Monotherapy: Durvalumab 1,500 mg on week 0.

Patients will attend a safety follow-up visit 90 days after study treatment discontinuation. Thereafter, patients will be contacted by phone or electronic communication every 3 months for survival status up to 5 years following date of first patient treatment initiation. All patients will be followed for a minimum of 6 months following enrolment of last patient. It is anticipated that the total enrolment period for the overall study will be approximately 2 to 3 years, with an overall duration of approximately 5 years

02

Conditions studied

  • Advanced Solid Malignancies

Keywords

  • Programmed death ligand 1 (PD-L1)
  • Cytotoxic T-lymphocyte antigen-4 (CTLA-4)
  • Durvalumab in combination with tremelimumab
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must have a of at least 12 weeks.
  2. Age ≥18 years at the time of screening. For patients aged \<20 years and enrolled in Japan, a written should be obtained from the patient and his or her legally acceptable representative
  3. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. Written informed consent and any locally required authorization (eg, Health Insurance Portability and Accountability Act in the US, European Union [EU] Data Privacy Directive in the EU) obtained from the patient/legal representative prior to performing any protocol-related procedures, including screening evaluations. For patients aged \<20 years and enrolling in Japan, a written informed consent should be obtained from the patient and his or her legally acceptable representative.
  4. Disease not amenable to curative surgery
  5. (ECOG) performance status as defined in the specific module.
  6. Body weight >30 kg.
  7. No prior exposure to or anti-PD-L1, including on another AstraZeneca study. Exposure to other agents may be permitted after discussion with the Sponsor.
  8. Adequate organ and marrow function as defined below

    • ≥9.0 g/dL
    • ≥1.0 × 109 /L
    • count ≥75 × 109/L
    • Serum ≤1.5 × the (ULN). This will not apply to patients with confirmed Gilbert's syndrome, who will be allowed in consultation with their physician.
    • and AST ≤2.5 × ULN; for patients with hepatic , ALT and AST ≤5 × ULN
    • Measured (CL) >40 mL/min or calculated creatinine clearance (CL) >40 mL/min as determined by Cockcroft-Gault (using actual body weight)

    Males:

    Creatinine CL = Weight (kg) × (140 - Age) (mL/min) 72 × serum creatinine (mg/dL)

    Females:

    Creatinine CL = Weight (kg) × (140 - Age) x 0.85 (mL/min) 72 × serum creatinine (mg/dL)

  9. Female patients of (ie, not surgically sterile or post menopausal) who are sexually active with a non sterilized male partner must use at least one highly effective method of from the time of screening and must agree to continue using such precautions for 180 days after the last dose of durvalumab + tremelimumab combination therapy or 90 days after the last dose of durvalumab monotherapy (see Section 3.8 and specifically Table 1).
  10. Evidence of status or negative urinary or serum pregnancy test (per Section 4) for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:
  11. Women \<50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle- stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy).

Women ≥50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses >1 year ago, had chemotherapy-induced menopause with last menses >1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).

Non sterilized male patients who are sexually active with a female partner of childbearing potential must use a male condom plus spermicide from screening through 180 days after receipt of the final dose of durvalumab + tremelimumab combination therapy or 90 days after receipt of the final dose of durvalumab monotherapy.

Exclusion criteria

Exclusion criteria:

  1. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
  2. Previous IP assignment in the present study.
  3. Concurrent enrollment in another clinical study, or another sub-study of this protocol, unless it is an observational (non-interventional) clinical study or during the follow up period of an interventional study.
  4. Participation in another clinical study with an product during the last 28 days or 5 half-lives, whichever is longer, prior to the first dose of study treatment.
  5. Any concurrent chemotherapy, investigational agent, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer-related conditions (eg, hormone replacement therapy) is acceptable.
  6. Local treatment of isolated lesions for palliative intent is acceptable (eg, local surgery or radiotherapy).
  7. Receipt of any investigational anticancer therapy within 28 days or 5 half-lives, whichever is longer, prior to the first dose of study treatment.
  8. Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of the first dose of study drug. Note: Local treatment of isolated lesions, excluding target lesions, for palliative intent is acceptable.
  9. Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of IP. Note: Local surgery of isolated lesions for palliative intent is acceptable.
  10. History of allogenic organ transplantation.
  11. Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, ILD, serious chronic GI conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written
  12. History of another primary except for

    • Malignancy treated with curative intent and with no known active disease ≥5 years before the first dose of investigational product (durvalumab + tremelimumab) and of low potential risk for recurrence
    • Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
    • Adequately treated carcinoma in situ without evidence of disease
  13. History of
  14. Has untreated central nervous system (CNS) and/or carcinomatous meningitis identified either on baseline brain imaging (please refer to for details on the imaging modality) obtained during the screening period or identified prior to signing the ICF. Patients whose have been treated may participate provided they show radiographic stability (defined as 2 brain images, both of which are obtained after treatment to the brain metastases. These imaging scans should both be obtained at least 4 weeks apart and show no evidence of intracranial progression). In addition, any neurologic symptoms that developed either as a result of the brain metastases or their treatment must have resolved or be stable either, without the use of , or are stable on a steroid dose of ≤10 mg/day of prednisone or its equivalent and anti-convulsants for at least 14 days prior to the start of treatment. Brain metastases will not be recorded as RECIST Target Lesions at baseline.
  15. History of active primary immunodeficiency.
  16. Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and tuberculosis testing in line with local practice), (known positive hepatitis B virus [HBV] surface antigen (HBsAg) result), , or (positive HIV 1/2 antibodies). Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
  17. Current or prior use of medication within 14 days before the first dose of durvalumab or tremelimumab. The following are exceptions to this criterion:

    • Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra articular injection)
    • Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent
  18. Active or prior documented or inflammatory disorders (including inflammatory bowel disease [eg, colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc.]). The following are exceptions to this criterion:

    • Patients with vitiligo or alopecia
    • Patients with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement
    • Any chronic skin condition that does not require systemic therapy
    • Patients without active disease in the last 5 years may be included but only after consultation with the study physician
    • Patients with celiac disease controlled by diet alone
  19. Receipt of within 30 days prior to the first dose of IP. Note: Patients, if enrolled, should not receive live vaccine whilst receiving IP and up to 30 days after the last dose of IP.
  20. Known allergy or to study drug(s) or compounds of similar biologic composition to the study drug(s), or any of the study drug .
  21. Any unresolved Grade ≥2 toxicities from prior anti cancer therapy with the exception of vitiligo, alopecia, and the laboratory values defined in the inclusion criteria.

    • Patients with Grade ≥2 neuropathy will be evaluated on a case-by-case basis after consultation with the Study Physician.
    • Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab or tremelimumab may be included only after consultation with the Study Physician
  22. For women only, currently pregnant (confirmed with positive pregnancy test) or breast feeding.
  23. Female patients who are pregnant or breastfeeding or male or female patients of who are not willing to employ effective from screening to 180 days after the last dose of durvalumab + tremelimumab combination therapy or 90 days after the last dose of durvalumab monotherapy.
  24. Prior randomization or treatment in a previous durvalumab and/or tremelimumab clinical study regardless of treatment arm assignment.
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
867 participants (actual)

Study arms

  • Experimental
    Combination therapy

    Combination therapy (durvalumab + tremelimumab) : Patients will receive the combination therapy followed by monotherapy via intravenous (IV) infusion once Q4W: * Durvalumab 1,500 mg + tremelimumab 75 mg on Week 0, for up to a maximum of 4 doses (or cycles) and * Durvalumab 1,500 mg starting 4 weeks after the last infusion of the combination or discontinuation of tremelimumab.

    Biological: MEDI4736 (Durvalumab) · Biological: MEDI4736 (Durvalumab) + Tremelimumab

  • Experimental
    Monotherapy

    Monotherapy (Durvalumab 1,500 mg): Patients will receive durvalumab 1,500 mg via IV infusion Q4W on Week 0.

    Biological: MEDI4736 (Durvalumab)

Interventions

  • A human monoclonal antibody (mAb) of the immunoglobulin G (IgG) 1 kappa subclass that blocks the interaction of PD-L1 (but not programmed cell death ligand-2) with PD-1 on T cells and CD80 (B7.1) on immune cells (IC).

  • BiologicalMEDI4736 (Durvalumab) + Tremelimumab

    Drug page: Durvalumab

    Durvalumab: A human mAb of IgG 1 kappa subclass that blocks the interaction of PD-L1 (but not programmed cell death ligand-2) with PD-1 on T cells and CD80 (B7.1) on IC. Tremelimumab: A human Ig G2 mAb that completely blocks the interaction of human CTLA-4 (cluster of differentiation \[CD\]152) with CD80 and CD86 and increase release of cytokines (interleukin \[IL\]-2 and interferon \[IFN\]-γ) from human T cells, peripheral blood mononuclear cells and whole blood.

This study also gives Tremelimumab. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events of Special Interest (AESIs)

    Incidence, severity, nature, seriousness, intervention/treatment, outcome, and causality of AESIs were assessed. AESIs included events with a potential inflammatory or immune-mediated mechanism that required interventions such as steroids, immunosuppressants, and/or hormone replacement therapy.

    Time frame: From screening to safety follow up visit (90 days after last dose), up to approximately 3 years.

Secondary outcomes

  1. Overall Survival

    Overall survival was defined as the time from the first date of treatment until death due to any cause.

    Time frame: From screening to final data cutoff (maximum up to 4 years) following date of first patient treatment initiation.

  2. Number of Participants With Adverse Events

    Incidence, severity, nature, seriousness, intervention/treatment, outcome, and causality of treatment-emergent AEs (including SAEs) will be assessed

    Time frame: From screening to safety follow up visit (90 days after last dose), maximum up to 4 years.

07

Results

Posted Jun 15, 2021

Participant flow

Participants who met all the inclusion and none of the exclusion criteria were randomized at 77 study centers across 8 countries (Canada, France, Germany, Italy, Republic of Korea, Netherlands, United Kingdom and United States of America).

Participant flow — Overall Study
MilestoneDurvalumab
Started867
Completed0
Not completed867
Withdrew: Development of study specific discontinuation criteria2
Withdrew: Condition under investigation worsened84
Withdrew: Lack of therapeutic response2
Withdrew: Protocol violation1
Withdrew: Adverse event73
Withdrew: Withdrawal by subject12
Withdrew: Disease relapse181
Withdrew: Subjective disease progression359
Withdrew: Other (as recorded)33
Withdrew: Patients who were still on study treatment at data cutoff120

Outcome measures

PrimaryNumber of Participants With Adverse Events of Special Interest (AESIs)

Incidence, severity, nature, seriousness, intervention/treatment, outcome, and causality of AESIs were assessed. AESIs included events with a potential inflammatory or immune-mediated mechanism that required interventions such as steroids, immunosuppressants, and/or hormone replacement therapy.

Time frame:
From screening to safety follow up visit (90 days after last dose), up to approximately 3 years.
Reported as:
Number · participants
Number of Participants With Adverse Events of Special Interest (AESIs)
participantsAESIAEPIimAE
Any adverse event (AE)26530097
Any AE of common terminology criteria for AEs Grade 3 or 4214917
Any serious adverse event (SAE) (including events with outcome = death)191311
Any AE with outcome = death100
Any AE, causally related to treatment19114587
Any AE of common terminology criteria Grade 3 or 4, causally related to treatment152016
Any SAE, causally related to treatment14310
Any AE with outcome = death, causally related to treatment100
Any AE leading to discontinuation of study treatment12710
Event outcome resolved14011932
Event outcome not resolved12418165
SecondaryOverall Survival

Overall survival was defined as the time from the first date of treatment until death due to any cause.

Time frame:
From screening to final data cutoff (maximum up to 4 years) following date of first patient treatment initiation.
Reported as:
Median · months
Overall Survival
monthsDurvalumab
Overall Survival7.0 (6.44 to 8.18)
SecondaryNumber of Participants With Adverse Events

Incidence, severity, nature, seriousness, intervention/treatment, outcome, and causality of treatment-emergent AEs (including SAEs) will be assessed

Time frame:
From screening to safety follow up visit (90 days after last dose), maximum up to 4 years.
Reported as:
Number · participants
Number of Participants With Adverse Events
participantsDurvalumab
Any AE787
Any AE causally related to any study treatment407
Any AE of common terminology criteria grade 3 or higher365
Any AE of common terminology criteria grade 3 or higher, causally related to study treatment78
Any AE with outcome = death42
Any AE with outcome = death causally related to study treatment9
Any SAE (including events with outcome = death)254
Any SAE (including events with outcome = death) causally related to study treatment41
Any AE leading to discontinuation of study treatment77
Any AE leading to discontinuation of study treatment causally related to study treatment33

Adverse events

Collected over From screening to safety follow up visit (90 days after last dose), maximum up to 4 years.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Durvalumab600/867 (69.2%)254/867 (29.3%)669/867 (77.2%)
Most frequent serious events
Showing 10 of 180
Most frequent serious events
EventDurvalumab
SepsisInfections and infestations18/867
Urinary tract infectionInfections and infestations17/867
Tumour hyperprogressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)11/867
PyelonephritisInfections and infestations8/867
Acute kidney injuryRenal and urinary disorders8/867
Device related infectionInfections and infestations7/867
DiarrhoeaGastrointestinal disorders7/867
HaematuriaRenal and urinary disorders7/867
Pulmonary embolismRespiratory, thoracic and mediastinal disorders7/867
General physical health deteriorationGeneral disorders7/867
Most frequent other events
Showing 10 of 21
Most frequent other events
EventDurvalumab
AstheniaGeneral disorders228/867
AnaemiaBlood and lymphatic system disorders172/867
ConstipationGastrointestinal disorders171/867
Decreased appetiteMetabolism and nutrition disorders149/867
DiarrhoeaGastrointestinal disorders136/867
NauseaGastrointestinal disorders126/867
PruritusSkin and subcutaneous tissue disorders109/867
CoughRespiratory, thoracic and mediastinal disorders84/867
Urinary tract infectionInfections and infestations84/867
FatigueGeneral disorders83/867

Baseline characteristics

Age, Continuous
Age, Continuous(years)Durvalumab
Mean67.5 ± 9.36
Sex: Female, Male
Sex: Female, Male(Participants)Durvalumab
Female173
Male694
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Durvalumab
American Indian or Alaska Native0
Asian65
Native Hawaiian or Other Pacific Islander0
Black or African American2
White508
More than one race0
Unknown or Not Reported28
08

Study locations

79 sites
  • Research Site
    Santa Rosa, California 95403, United States
  • Research Site
    Washington, District of Columbia 20007, United States
  • Research Site
    Tinley Park, Illinois 60487, United States
  • Research Site
    Omaha, Nebraska 68130, United States
  • Research Site
    Hackensack, New Jersey 07601, United States
  • Research Site
    East Setauket, New York 11733, United States
  • Research Site
    Greenville, South Carolina 29607, United States
  • Research Site
    Knoxville, Tennessee 37920, United States
  • Research Site
    Blacksburg, Virginia 24060, United States
  • Research Site
    Spokane, Washington 99208, United States
  • Research Site
    Moncton, New Brunswick E1C 6Z8, Canada
  • Research Site
    Brampton, Ontario L6R 3J7, Canada
  • Research Site
    Hamilton, Ontario L8V 5C2, Canada
  • Research Site
    Kingston, Ontario K7L 5P9, Canada
  • Research Site
    London, Ontario N6A 4L6, Canada
  • Research Site
    Newmarket, Ontario L3Y 2P9, Canada
  • Research Site
    Toronto, Ontario M4N 3M5, Canada
  • Research Site
    Toronto, Ontario M5G 2M9, Canada
  • Research Site
    Greenfield Park, Quebec J4V 2H1, Canada
  • Research Site
    Quebec, G1R 2J6, Canada
  • Research Site
    Besançon Cedex, 25030, France
  • Research Site
    Bordeaux Cedex, 33075, France
  • Research Site
    Bordeaux, 33076, France
  • Research Site
    Brest, 29609, France
  • Research Site
    Dijon, 21034, France
  • Research Site
    Lille, 59000, France
  • Research Site
    Lyon Cedex 08, 69373, France
  • Research Site
    Marseille, 13005, France
  • Research Site
    Montpellier, 34298, France
  • Research Site
    Nice, 6189, France
  • Research Site
    Nimes, 30029, France
  • Research Site
    Paris, 75010, France
  • Research Site
    Pierre Benite, 69495, France
  • Research Site
    Poitiers Cedex, 86021, France
  • Research Site
    Rouen, 76031, France
  • Research Site
    Saint Herblain Cedex, 44805, France
  • Research Site
    STRASBOURG Cedex, 67065, France
  • Research Site
    Toulouse, 31059, France
  • Research Site
    Tours CEDEX, 37044, France
  • Research Site
    Villejuif, 94805, France
  • Research Site
    Berlin, 13585, Germany
  • Research Site
    Bielefeld, 33611, Germany
  • Research Site
    Dresden, 01307, Germany
  • Research Site
    Duisburg, 47179, Germany
  • Research Site
    Erlangen, 91054, Germany
  • Research Site
    Essen, 45136, Germany
  • Research Site
    Guetersloh, 33332, Germany
  • Research Site
    Hamburg, 20246, Germany
  • Research Site
    Jena, 07747, Germany
  • Research Site
    Kiel, 24116, Germany
  • Research Site
    Münster, 48149, Germany
  • Research Site
    Stuttgart, 70174, Germany
  • Research Site
    Würzburg, 97080, Germany
  • Research Site
    Ancona, 60126, Italy
  • Research Site
    Arezzo, 52100, Italy
  • Research Site
    Avellino, 83100, Italy
  • Research Site
    Bari, 70124, Italy
  • Research Site
    Catania, 95126, Italy
  • Research Site
    Lecce, 73100, Italy
  • Research Site
    Meldola, 47014, Italy
  • Research Site
    Milano, 20141, Italy
  • Research Site
    Modena, 41124, Italy
  • Research Site
    Padova, 35128, Italy
  • Research Site
    Pisa, 56126, Italy
  • Research Site
    Ravenna, 48100, Italy
  • Research Site
    Roma, 00128, Italy
  • Research Site
    Roma, 00152, Italy
  • Research Site
    Rozzano, 20089, Italy
  • Research Site
    Udine, 33100, Italy
  • Research Site
    Busan, 49241, Korea, Republic of
  • Research Site
    Goyang-si, 10408, Korea, Republic of
  • Research Site
    Seoul, 03722, Korea, Republic of
  • Research Site
    Seoul, 05505, Korea, Republic of
  • Research Site
    Leiden, 2333 ZA, Netherlands
  • Research Site
    London, EC1A 7BE, United Kingdom
  • Research Site
    London, W1G 6AD, United Kingdom
  • Research Site
    London, W6 8RF, United Kingdom
  • Research Site
    Newcastle, NE7 7DN, United Kingdom
  • Research Site
    Sheffield, S10 2SJ, United Kingdom
09

References and documents

Publications

  • Sonpavde GP, Sternberg CN, Loriot Y, Marabelle A, Lee JL, Flechon A, Roubaud G, Pouessel D, Zagonel V, Calabro F, Banna GL, Shin SJ, Vera-Badillo FE, Powles T, Hellmis E, Miranda PAP, Lima AR, Emeribe U, Oh SM, Hotte SJ. Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma. Eur J Cancer. 2022 Mar;163:55-65. doi: 10.1016/j.ejca.2021.12.012. Epub 2022 Jan 15. PubMed 35042068 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2017 to primary completion in Mar 2020, 33 months.

Results were first posted in Jun 2021, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2017
First posted
Mar 21, 2017
StartActual
Jun 5, 2017
Primary completionActual
Mar 31, 2020
CompletionActual
Dec 16, 2022
Results first posted
Jun 15, 2021
Last update
Dec 22, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03084471
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Mar 21, 2017
Start date
Jun 5, 2017
Primary completion
Mar 31, 2020
Completion
Dec 16, 2022
Results posted
Jun 15, 2021
Last update
Dec 22, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Durvalumab · Tremelimumab

Start the discussion